ZITHROMAX INJECTION Rx
Generic Name and Formulations:
Azithromycin 500mg/vial; for IV infusion after reconstitution and dilution.
Indications for ZITHROMAX INJECTION:
Susceptible infections including community-acquired pneumonia, pelvic inflammatory disease (PID).
Give by IV infusion 1mg/mL over 3hrs or 2mg/mL over 1hr. ≥16yrs: Pneumonia: 500mg once daily for at least 2 days, switch to 500mg orally once daily, for a total of 7–10 days combined therapy. PID: 500mg once daily for 1–2 days, switch to 250mg orally once daily for a total of 7 days combined therapy.
<16yrs: not established.
Ketolide allergy. History of cholestatic jaundice/hepatic dysfunction associated with prior use.
Pneumonia: oral treatment is for mild, community-acquired cases suitable for outpatient therapy only. Discontinue if signs/symptoms of hepatitis occur. Known QT prolongation, proarrhythmic conditions, clinically significant bradycardia: avoid. Allergic symptoms may recur after initial successful symptomatic treatment. Myasthenia gravis. Hepatic or renal impairment. Elderly. Pregnancy (Cat.B). Nursing mothers.
Avoid concomitant aluminum- or magnesium-containing antacids. Monitor with digoxin, phenytoin, warfarin. Monitor for azithromycin toxicity (eg, liver dysfunction, ototoxicity) with nelfinavir. Concomitant Class 1A (eg, quinidine, procainamide), or Class III (eg, dofetilide, amiodarone, sotalol) antiarrhythmics, or others known to prolong the QT interval: avoid.
Diarrhea, nausea, abdominal pain, vomiting, rash; hepatotoxicity, hypersensitivity reactions (eg, angioedema, AGEP, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS; discontinue if occurs), torsade de pointes (esp. elderly), C. difficile associated diarrhea.
Biliary (primarily), renal.
Tabs—30; Z-Pak (6 x 250mg tabs)—3; Tri-Pak (3 x 500mg tabs)—3; Susp 100mg/5mL—15mL; 200mg/5mL—15mL, 22.5mL, 30mL; Single Dose Packets—3, 10; Inj—10
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Computerized Training Programs for Schizophrenia Improve Cognitive Functioning
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Attention-Deficit/Hyperactivity Disorder Increasing Among US Children and Adolescents
- Cost-Effective Telehealth Alternatives for Veterans With Depression
- Polygenic Risk Scores Could Aid in Identifying Bipolar Disorder, Schizophrenia
- Brief Impression Questionnaire Useful in Schizophrenia Diagnoses